Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 15
Submit an article Journal homepage
191
Views
19
CrossRef citations to date
0
Altmetric
Review

The therapeutic management of differentiated thyroid cancer

Jennifer A Sipos University of Florida, 1600 Archer Road, PO Box 100226, Gainesville, FL 32610, USA +1 352 846 2247; +1 352 846 2231; [email protected]
&
Ernest L Mazzaferri University of Florida, 1600 Archer Road, PO Box 100226, Gainesville, FL 32610, USA +1 352 846 2247; +1 352 846 2231; [email protected]; The Ohio State University, Columbus, Ohio, USA
Pages 2627-2637 | Published online: 19 Sep 2008

Bibliography

  • Cady B. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462-8
  • Schlumberger MJ. Medical progress – papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306
  • Duren M, Yavuz N, Bukey Y, et al. Impact of initial surgical treatment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deficient region. World J Surg 2000;24(11):1290-4
  • Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL, Samaan N, editors, Endocrine tumors. Cambridge: Blackwell Scientific Publications, Inc.; 1993. p. 278-333
  • Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984;53:982-92
  • Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998;83(3):553-9
  • Moosa M, Mazzaferri EL. Occult thyroid carcinoma. Cancer J 1997;10:180-8
  • Tourniaire J, Bernard MH, Bizollon-Roblin MH, et al. Papillary microcarcinoma of the thyroid. 179 cases reported since 1973. Presse Med 1998;27(29):1467-9
  • Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-66
  • Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109-41
  • Hay ID, Bergstralh EJ, Grant CS, et al. Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. Surgery 1999;126(6):1173-81
  • Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-8
  • Samaan NA, Maheshwari YK, Nader S, et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 1983;56:1131-8
  • Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940 – 1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26(8):879-85
  • Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246(3):375-81
  • Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 1990;160:341-3
  • Haveman JW, Van Tol KM, Rouwe CW, et al. Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol 2003;10(1):15-20
  • Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134(6):946-54
  • White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007;31(5):895-904
  • Scheumann GF, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994;18(4):559-67
  • Tisell LE, Nilsson B, Molne J, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996;20(7):854-9
  • Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 1996;18(2):127-32
  • McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991;162:353-7
  • Cheah WK, Arici C, Ituarte PH, et al. Complications of neck dissection for thyroid cancer. World J Surg 2002;26(8):1013-6
  • Henry JF, Gramatica L, Denizot A, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998;383(2):167-9
  • Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320-8
  • Kozak OV, Muzichenko LV, Trembach AM, et al. First treatment activity and outcome of radioiodine therapy in thyroid cancer patients with metastases in lymph nodes: mathematical correlation and clinical implications. Exp Oncol 2006;28(1):75-9
  • Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26(1):22-8
  • Wada N, Suganuma N, Nakayama H, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg 2007;392(4):417-22
  • Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 2004;28(5):498-501
  • Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with ‘berry picking’ than neck dissection in thyroid cancer. Am Surg 2003;69(3):191-6
  • Gemsenjager E, Perren A, Seifert B, et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003;197(2):182-90
  • Kim ES, Kim TY, Koh JM, et al. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf) 2004;61(1):145-8
  • Pasieka JL, Thompson NW, McLeod MK, et al. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg 1992;16(4):711-6
  • De Jong SA, Demeter JG, Lawrence AM, Paloyan E. Necessity and safety of completion thyroidectomy for differentiated thyroid carcinoma. Surgery 1992;112:734-7
  • Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer – a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:1132-6
  • Scheumann GFW, Seeliger H, Musholt TJ, et al. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Eur J Surg 1996;162:677-84
  • Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996;20:88-93
  • Vassilopoulou-Sellin R, Klein MJ, Smith TH, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993;71:1348-52
  • Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7
  • Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229-42
  • Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82(2):375-88
  • Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 1977;50:799-807
  • Leboeuf R, Perron P, Carpentier AC, et al. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clin Endocrinol (Oxf) 2007;67(6):839-44
  • Duntas LH, Biondi B. Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol 2007;156(1):13-9
  • Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85
  • Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91(3):926-32
  • Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16(11):1121-30
  • Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6
  • Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47(4):648-54
  • Borget I, Corone C, Nocaudie M, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007;156(5):531-8
  • Mernagh P, Campbell S, Dietlein M, et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006;155(3):405-14
  • Borget I, Remy H, Chevalier J, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 2008;35:1457-63
  • Maxon HR, Boehringer TA, Drilling J. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 1983;8:123-6
  • Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2003;58(4):428-35
  • Costa A, Testori OB, Cenderelli C, et al. Iodine content of human tissues after administration of iodine containing drugs or contrast media. J Endocrinol Invest 1978;1(3):221-5
  • Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun 2005;26(8):731-5
  • Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. Thyroid 2003;13(4):333-40
  • Muratet JP, Giraud P, Daver A, et al. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med 1997;38:1362-8
  • Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med 2000;41(7):1198-202
  • Urhan M, Dadparvar S, Mavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 2007;34(7):1012-7
  • Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47(10):1587-91
  • Bal C, Padhy AK, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77(12):2574-80
  • Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2000;52(6):765-73
  • Van Nostrand D, Atkins F, Yeganeh F, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002;12(2):121-34
  • Brierley J, Maxon HR. Radioiodine and external radiation therapy. In: Fagin JA, editor, Thyroid cancer. Boston/Dordrecht London: Kluwer Academic Publishers; 1998. p. 285-317
  • Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-34
  • Souza Rosario PW, Barroso AL, Rezende LL, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med 2004;29(12):795-8
  • Pons F, Carrio I, Estorch M, et al. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 1987;8:644-7
  • Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:912-6
  • Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med 1986;27:637-40
  • DiRusso G, Kern KA. Comparative analysis of complications from I-131 radioablation for well-differentiated thyroid cancer. Surgery 1994;116:1024-30
  • Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93(2):504-15
  • Rubino C, De Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89(9):1638-44
  • Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002;87(12):5817-20
  • Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8(9):737-44
  • McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34(7-8):554-64
  • Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-8
  • Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331(19):1249-52
  • Toivonen J, Tahtela R, Laitinen K, et al. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 1998;138:667-73
  • Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73
  • Marcocci C, Golia F, Vignali E, Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 1997;12:72-7
  • Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61(1):61-74
  • Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139(5 Pt 1):346-51
  • Bachelot A, Leboulleux S, Baudin E, et al. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) 2005;62(3):376-9
  • Torlontano M, Crocetti U, Augello G, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006;91(1):60-3
  • Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88(4):1433-41
  • Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150(2):105-12
  • Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88(8):3668-73
  • Noguchi S, Yamashita H, Murakami N, et al. Small carcinomas of the thyroid – a long-term follow-up of 867 patients. Arch Surg 1996;131:187-91
  • Kloos RT, Mazzaferri EL. A single recombinant human thyrotrophin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90(9):5047-57
  • Schlumberger M, Mancusi F, Baudin E, Pacini F. 131-I Therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-6
  • Van Tol KM, Jager PL, De Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003;148(6):589-96
  • Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: comparison of patients treated with high 131-I activities versus untreated patients. J Clin Endocrinol Metab 2001;86(9):4092-7
  • Kabasakal L, Selcuk NA, Shafipour H, et al. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imaging 2004;31(11):1500-4
  • Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447-63
  • Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605
  • Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89(1):91-5
  • Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2006;90(12):6373-9
  • Jhiang SM, Caruso DR, Gilmore E, et al. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene 1992;7:1331-7
  • Ito Y, Arai K, Nozawa R, et al. S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res 2007;27(4C):2679-83
  • Min HS, Choe G, Kim SW, et al. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol 2008;21(6):748-55

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.